News

04/24/2026

Skyphos Technologies Has Been Awarded its Second U.S. Patent

Skyphos Technologies has been awarded its second U.S. patent, adding to a growing intellectual property portfolio that now includes nearly a dozen patent applications in process around the world. This latest patent secures core technologies and methods that allow micro-scale parts to be produced in seconds, at throughputs designed to exceed legacy manufacturing such as

04/23/2026

CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics

CollectiveMinds LLC, a leading executive search firm specializing in life sciences and healthcare, today announced the successful placement of Keith Meadors as Chief Commercial Officer of Genova Diagnostics, a pioneer in advanced diagnostic testing. The appointment marks another milestone for CollectiveMinds in connecting exceptional leadership talent with high-growth organizations across the diagnostics and life sciences

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response

04/22/2026

Luminoah Announces FDA Clearance of the Luminoah Flow Enteral Nutrition System, A Brighter Future for Tube Feeding

Luminoah, a medical technology company focused on modernizing enteral nutrition, today announced it has received U.S. Food and Drug Administration clearance for Luminoah Flow™, an enteral feeding system designed to improve the experience of patients who rely on tube feeding. Luminoah Flow combines portability, precision, and connected technology into a streamlined system designed for both

04/21/2026

GO Virginia Region 7 funds LIFT-VA

On Tuesday, March 24, 2026, GO Virginia Region 7 funded something the Commonwealth has not had before: a structured, credentialed pathway that takes students from their first day in a real biotechnology laboratory all the way to a career in one of the fastest-growing industries in America. The program is called Life-Sciences Innovation & Future

04/20/2026

Lumira Ventures Announces First Closing of Fifth Fund to Back High-Impact Healthcare Innovation Across North America

Lumira Ventures today announced the first closing of Lumira Ventures V, LP (“Fund V”), its latest healthcare venture capital fund dedicated to building transformative biotechnology and medical technology companies across North America. Together with three strategic funds managed by the firm, this closing represents the seventh investment fund established by Lumira. With a target final

04/15/2026

Gov. Spanberger and Homegrown Innovator Agrospheres Celebrate Launch of Virginia’s new Biomanufacturing Facility

AgroSpheres, Inc., a Charlottesville-based agricultural biotechnology company, officially opened its first commercial biomanufacturing facility, representing a milestone for AgroSpheres and the biotech ecosystem. Speakers at the ribbon-cutting ceremony included: Virginia Governor Abigail Spanberger, AgroSpheres co-founders CEO Payam Pourtaheri and CTO Ameer Shakeel, Albemarle County Chair of the Board of Supervisors Ned Gallaway, President of the

04/11/2026

Skyphos Technologies introduces additive lithography platform for microneedle

Skyphos Technologies, a Blacksburg, Virginia–based advanced manufacturing company, has introduced a fabrication platform it calls “additive lithography” — a volumetric approach to producing microscale structures for needle-free drug delivery patches and high-density diagnostic tests. The system uses digitally defined masks to build complete patch geometries in a single two-second exposure, without layer-by-layer processing, molds, or

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,

03/31/2026

Newby Op-Ed: Virginia wants to improve medicine affordability. This act will not do that.

For five years, Virginia lawmakers have tried to establish a state government entity to artificially set pricing levels for prescription drugs. With a proposal to do so once again on its way to our governor’s desk, it is worth pausing to ask whether this idea — unsuccessful in other states and, here, recast and renamed though

03/27/2026

CvilleBioHub Appoints Nikki Hastings as President, Marking New Phase of Growth and Regional Leadership

CvilleBioHub today announced that its Board of Directors has appointed Nikki Hastings as President, recognizing her leadership in building the organization into a cornerstone of Central Virginia’s life sciences ecosystem and positioning it for continued growth and influence. The appointment comes as CvilleBioHub prepares to celebrate its 10th anniversary and marks one year since the

03/25/2026

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide. Grenova and its division partners are backed by

03/25/2026

Virginia Startups Raise Record $2.9 Billion in Venture Capital Investment in 2025 – Highest in Commonwealth History

Virginia Innovation Partnership Corp. (VIPC) today announced that the National Venture Capital Association (NVCA) reported Virginia attracted $2.9 billion in venture capital investment in 2025, marking an all-time high for the Commonwealth according to the 2025 Q4 Pitchbook-NVCA Venture Monitor Report.1 This record level of investment reflects the continued growth and momentum of Virginia’s startup

03/24/2026

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros uniquesingle-molecule-counting platform and reinforcing its potential to improve

03/24/2026

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these